Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Non-Current Liabilities (2020 - 2023)

Candel Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $26.6 million for Q3 2023.

  • For Q3 2023, Total Non-Current Liabilities fell 5.83% year-over-year to $26.6 million; the TTM value through Sep 2023 reached $26.6 million, down 5.83%, while the annual FY2022 figure was $28.1 million, 312.19% up from the prior year.
  • Total Non-Current Liabilities for Q3 2023 was $26.6 million at Candel Therapeutics, down from $26.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $28.3 million in Q3 2022 and bottomed at $5.5 million in Q3 2021.
  • The 4-year median for Total Non-Current Liabilities is $26.6 million (2023), against an average of $19.7 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 411.57% in 2022 before it dropped 5.83% in 2023.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $6.0 million in 2020, then increased by 14.5% to $6.8 million in 2021, then skyrocketed by 312.19% to $28.1 million in 2022, then dropped by 5.3% to $26.6 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Total Non-Current Liabilities are $26.6 million (Q3 2023), $26.9 million (Q2 2023), and $26.4 million (Q1 2023).